Drug Discovery & Development Core (D3)

Advancing New Therapeutics to Improve Human Health

 

We provide funding, resources, and the expertise of a Therapeutic Advisory Panel to catalyze drug discovery, design, development, and delivery; preclinical and clinical pharmacology; regulatory processes; and commercialization.

Scientist holding petri dish

 

Computational, Synthesis, and Translational Cores

D3 leverages the infrastructure and Computational, Synthesis, and Translational Cores of the UK Center for Pharmaceutical Research and Innovation (CPRI) to support CCTS translational research projects. CPRI evolved into an NIGMS-supported P20 Center of Biomedical Research Excellence (COBRE) and will complement and leverage existing CCTS faculty mentorship infrastructure with an emphasis on ‘translational chemical biology’.
 


Therapeutic Advisory Panel

The Therapeutic Advisory Panel (TAP)  serves as the peer review panel for D3 pilot applications and provides consultation on drug discovery and development projects.

 

Drug Development Pilot Funding Awards 

This award is intended to support new drug discovery and development research with the goal of augmenting the translation of scientific discoveries to therapeutic development.  Specifically, the purpose is to assist in the transition from biology and target identification to clinical targets and to facilitate the transition of discovery through development and delivery to all phases of clinical trials and subsequent commercialization. A maximum of $50,000 will be awarded for a period of 18 months.
There is no open RFA at this time.

See previous awardees. »

 

Commercialization and Entrepreneurship

D3 is committed to advancing commercialization and entrepreneurship. We collaborate with KYNETIC (Kentucky Network for Innovation & Commercialization), which is one of five new NIH Research Evaluation and Commercialization Hubs (REACH) funded nationally in 2019 to provide product development funding and commercialization-related education, training expert consultation.  D3 co-director Linda Dwoskin serves as PI for KYNETIC, which is a collaboration of the University of Kentucky, the University of Louisville and the Kentucky Cabinet for Economic Development, with support from the Kentucky Commercialization Ventures (KCV) program.

We also collaborate with the UK Office of Technology and Commercialization on intellectual property development, licensing, and entrepreneurial activities. 

 

D3 seeks new opportunities to develop innovative research partnerships with UK investigators. For more information or to request services, please contact us.

 

Our Impact

14

Issued Patents Since 2016

456

Unique Compounds in Natural Products Repository  

119

D3 Peer Reviewed Publications

83

Projects to Date 

25

UK Departments Engaged 

$68.3 million

Grants Facilitated

Drug Discovery & Development News

  • Behind the Blue logo
    • Oct 13 2020

    Dr. Lisa Cassis, UK’s vice president for research, oversees the university’s vast medical and nonmedical research efforts. On this episode of "Behind the Blue," she discusses the many areas UK's Office of Research is prioritizing, including greater diversity and inclusion, the increasing commitment to opportunities for undergraduate research, returning research efforts to higher capacity during the COVID-19 pandemic, and more.

  • The COBRE grant will support four early career researchers, top: Carrie Shaffer, Gluck Equine Research Center, and Martha Grady, College of Engineering, bottom: Samuel G. Awuah, College of Arts & Sciences, and Vincent Venditto, College of Pharmacy.
    • Aug 4 2020

    Jon Thorson and UK were recently awarded a prestigious Centers of Biomedical Research Excellence (COBRE) grant to study translational chemical biology from the National Institutes of General Medical Sciences, part of the National Institutes of Health. The $11.2 million grant will fund UK's Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation.

  • Illustration of a COVID-19 particle
    • Jun 9 2020

    The program is a collaboration of the UK CURE Alliance and Center for Clinical and Translational Science, who together moved the funding mechanism from concept to first award in 20 days.